PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease - Report - MDSpire

PEPITEM Modulates the Synovial Environment in Immune-Mediated Inflammatory Arthritis to Mitigate Disease Progression

  • By

  • Mussarat Wahid

  • Samuel Kemble

  • Oladimeji Abudu

  • Anella Saviano

  • Christopher Mahony

  • Jonathan W. Lewis

  • Thomas A. Nicholson

  • Anna Schettino

  • Noemi Marigliano

  • Kathryn Frost

  • Jenefa Begum

  • Alyssa M. Urbanowski

  • Marion Limo

  • Rakesh Jha

  • Sandra Martinez Jarquin

  • Laleh Pezhman

  • Abbie E. A. Degan

  • Amy E. Anderson

  • Charlotte G. Smith

  • Armaiti Batki

  • Holly Adams

  • Francesco Caso

  • Raffaele Scarpa

  • Iain McInnes

  • Stefan Siebert

  • Arthur G. Pratt

  • Andrew Filer

  • Karim Raza

  • Adam P. Croft

  • Myriam Chimen

  • Felicity de Cogan

  • G. Ed Rainger

  • Asif J. Iqbal

  • Francesco Maione

  • Helen M. McGettrick

  • July 1, 2026

Share

PEPITEM Modulates the Synovial Environment in Immune-Mediated Inflammatory Arthritis

Overview

PEPITEM, an immunopeptide, is explored for its role in modulating the synovial environment in immune-mediated inflammatory arthritis, particularly in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). This study investigates the therapeutic efficacy of PEPITEM in limiting disease severity and modifying the composition of the synovial microenvironment in murine models.

Background

Immune-mediated inflammatory diseases (IMIDs) such as RA and PsA are characterized by the inappropriate accumulation and activation of leukocytes, leading to joint damage and disability. Current treatments primarily target pathogenic leukocyte populations but do not restore endogenous regulatory pathways. PEPITEM may offer a novel therapeutic approach by potentially restoring these pathways.

Data Highlights

No numerical data or trial data were provided in the source material.

Key Findings

  • PEPITEM levels are diminished in patients with IMIDs, including RA and PsA.
  • Supplementation of PEPITEM can limit leukocyte migration and disease severity in murine models of IMIDs.
  • Patients with RA exhibit elevated levels of adiponectin, which correlates with disease severity.
  • B cells from RA patients show reduced secretion of PEPITEM in response to adiponectin.

Clinical Implications

Further exploration of PEPITEM's role in clinical settings may provide insights into new treatment modalities for RA and PsA.

Conclusion

Further investigation into PEPITEM's role in modulating inflammation and disease progression in immune-mediated inflammatory arthritis is warranted.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
  6. Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative | Nature Reviews Rheumatology
  7. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
  8. Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative | Nature Reviews Rheumatology
  9. https://academic.oup.com/rheumatology/article/64/6/3255/7979252

Original Source(s)

PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease

  • by Mussarat Wahid, Samuel Kemble, Oladimeji Abudu, Anella Saviano, Christopher Mahony, Jonathan W. Lewis, Thomas A. Nicholson, Anna Schettino, Noemi Marigliano, Kathryn Frost, Jenefa Begum, Alyssa M. Urbanowski, Marion Limo, Rakesh Jha, Sandra Martinez Jarquin, Laleh Pezhman, Abbie E. A. Degan, Amy E. Anderson, Charlotte G. Smith, Armaiti Batki, Holly Adams, Francesco Caso, Raffaele Scarpa, Iain McInnes, Stefan Siebert, Arthur G. Pratt, Andrew Filer, Karim Raza, Adam P. Croft, Myriam Chimen, Felicity de Cogan, G. Ed Rainger, Asif J. Iqbal, Francesco Maione, Helen M. McGettrick

  • July 1, 2026

Related Content

Tenderness Tracks Ultrasound Findings

Joint tenderness showed broader associations with concurrent ultrasound abnormalities than patient-reported pain among anti-cyclic citrullinated peptide–positive patients without clinical arthritis.

Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.